跳至主要内容
临床试验/CTRI/2009/091/000964
CTRI/2009/091/000964已完成3 期

Evaluation of efficacy and safety of naftopidil versus tamsulosin for the treatment of benign prostatic hyperplasia: a randomized, open - label, comparative, active controlled, multi-centre trial.

Sun Pharmaceutical Industries Ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Male patients aged between 50-80 years.
  • 2.Patients with diagnosis of BPH.
  • 3.Patients with IPSS total score of ≥8
  • 4.Patient willing to give their informed consent

排除标准

  • 1.Patients having history of allergy to Alpha1 - adrenoceptor antagonists.
  • 2.Patients on treatment with antiandrogen drugs.
  • 3.Patients on current therapy with any Alpha1 - adrenoceptor antagonist.
  • 4.Patients taking any drug with anticholinergic activity.
  • 5.Patients with significant history of orthostatic hypotension.
  • 6.Patients with concomitant neurological diseases, known or suspected neurogenic bladder dysfunction.
  • 7.Patients with carcinoma of the prostate or bladder previous surgery for BPH or bladder neck obstruction.
  • 8.Patients with history of recurrent UTI or Concomitant active UTI.
  • 9.Patients who have serious mental illness.
  • 10.Patient who have serious disorder with respect to cerebral blood vessels.
  • 11.Patients who are taking drugs, which have phosphodiesterese 5 inhibitory action

研究者

相似试验